| 1 |
NCT03467581 |
Recruiting |
Five-year Outcome of Laparoscopic Gastric Sleeve |
- Bariatric Surgeries
- Metabolic Surgery
|
|
Observational |
|
- Tartu University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Five-year outcome of laparoscopic gastric sleeve
|
500 |
All |
18 Years to 65 Years (Adult) |
NCT03467581 |
Sleeve5years |
|
October 8, 2008 |
December 31, 2028 |
December 31, 2028 |
March 16, 2018 |
March 16, 2018 |
|
- Tartu University Hospital
Tartu, Estonia
|
| 2 |
NCT03160261 |
Enrolling by invitation |
Effect of Exenatide on Cortisol Secretion |
|
- Drug: Exenatide Injection
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Cortisol peak
- Adrenocorticotropin (ACTH) peak
- Glucose
- Growth hormone
|
10 |
All |
18 Years to 50 Years (Adult) |
NCT03160261 |
Ex17 |
|
September 7, 2017 |
December 30, 2017 |
December 30, 2017 |
May 19, 2017 |
September 11, 2017 |
|
- Tartu University Hospital
Tartu, Estonia
|
| 3 |
NCT03145519 |
Recruiting |
A Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population |
- Injections, Intravenous
- Administration, Intravenous
|
- Device: Vasofix Certo Catheter
- Device: OptiVein Catheter
|
Interventional |
Not Applicable |
- Optomeditech Oy
- CardioMed Device Consultants
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- First attempt success rate
- Number of attempts
- Time to successful IV insertion
- (and 5 more...)
|
188 |
All |
up to 12 Years (Child) |
NCT03145519 |
OMT-CT-004-PED |
|
February 15, 2017 |
May 30, 2017 |
June 30, 2017 |
May 9, 2017 |
May 9, 2017 |
|
- Tartu University Hospital, Children's Clinic
Tartu, Estonia
|
| 4 |
NCT02944292 |
Recruiting |
Effect of Sedation on Intra-abdominal Pressure |
- Intra-abdominal Hypertension
|
- Procedure: Deepening of sedation
- Drug: Propofol
|
Interventional |
Phase 4 |
- Tartu University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intra-abdominal pressure
- Richmond Agitation-Sedation Scale
- Spontaneous and total respiratory rate
- (and 6 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02944292 |
16062 |
|
November 2016 |
December 2018 |
December 2018 |
October 25, 2016 |
December 8, 2017 |
|
- Tartu University Hospital
Tartu, Tartumaa, Estonia
|
| 5 |
NCT02700958 |
Recruiting |
Remote Ischemic Preconditioning as a Method Against Subclinical Renal Injury and Contrast-induced Nephropathy |
- Atherosclerosis
- Stable Angina
- Peripheral Artery Disease
- Contrast-induced Nephropathy
|
- Procedure: Remote ischemic preconditioning
- Procedure: SHAM Remote ischemic preconditioning
|
Interventional |
Not Applicable |
- Tartu University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change in carotid-femoral pulse wave velocity compared with baseline and SHAM subgroup
- Change in augmentation indices (augmentation index and heart rate-corrected augmentation index (AIx@75)) compared with baseline and SHAM subgroup
- Cardiac markers
- (and 12 more...)
|
160 |
All |
18 Years and older (Adult, Senior) |
NCT02700958 |
16003 |
|
February 2016 |
August 2018 |
December 2018 |
March 7, 2016 |
February 27, 2018 |
|
- Tartu University Hospital
Tartu, Tartu County, Estonia
|
| 6 |
NCT02689414 |
Completed |
A Study of Remote Ischaemic Preconditioning in Patients With Atherosclerosis Undergoing Vascular Surgery |
- Abdominal Aortic Aneurysm
- Peripheral Artery Disease
- Carotid Artery Stenosis
|
- Procedure: Remote ischaemic preconditioning
- Procedure: Control to RIPC
|
Interventional |
Not Applicable |
- Tartu University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Prevention
|
- Carotide-femoral pulse velocity
- Augmentation index
- Cardiac markers
- (and 12 more...)
|
98 |
All |
18 Years and older (Adult, Senior) |
NCT02689414 |
16004 |
|
January 2016 |
February 8, 2018 |
February 2019 |
February 24, 2016 |
February 28, 2018 |
|
- Tartu University Hospital
Tartu, Tartu County, Estonia
|
| 7 |
NCT02662543 |
Active, not recruiting |
The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- The impact of rotavirus vaccination on hospitalizations due to acute gastroenteritis
- The severity of disease according to Vesikari and Clark severity scales
|
2260 |
All |
up to 18 Years (Child, Adult) |
NCT02662543 |
224/T-3 |
ERVS |
February 2015 |
August 2018 |
August 2020 |
January 25, 2016 |
December 21, 2016 |
|
- Department of Microbiology, University of Tartu
Tartu, Estonia
|
| 8 |
NCT02613000 |
Recruiting |
Intestinal-Specific Organ Function Assessment (iSOFA Study) |
- Critical Illness
- Multiple Organ Failure
|
|
Observational |
|
- University of Tartu
- Karolinska University Hospital
- University Hospital Inselspital, Berne
- Vienna General Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT02613000 |
iSOFA Study |
iSOFA |
April 2015 |
March 2018 |
March 2018 |
November 24, 2015 |
October 25, 2016 |
|
- Tartu University Hospital
Tartu, Estonia
|
| 9 |
NCT02089256 |
Completed |
Effect of Repeated Administration of Liraglutide on Insulinogenic Indices |
|
|
Interventional |
Phase 4 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the glucose-sensitivity of the beta cells
- Effects on adrenal hormones
|
10 |
All |
18 Years to 50 Years (Adult) |
NCT02089256 |
LI20/1101 |
|
June 2014 |
March 2015 |
March 2015 |
March 17, 2014 |
April 1, 2015 |
|
- Tartu University Hospital
Tartu, Estonia
|
| 10 |
NCT01369056 |
Completed |
HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence |
- Acute HIV Infection
- Acquired Immunodeficiency Syndrome
- Medication Adherence
|
- Behavioral: Advanced Adherence Counseling (AdvAdh)
|
Interventional |
Not Applicable |
- University of Tartu
- State University of New York - Downstate Medical Center
- Tibotec Pharmaceutical Limited
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
|
- Change in HAART adherence level (HIV RNA and CD4 count)
- Study subjects retention in study
- Change in quality of life of study subjects
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT01369056 |
MARTH07237 |
|
July 2010 |
December 2011 |
December 2011 |
June 8, 2011 |
May 26, 2016 |
|
- Ida-Viru Central Hospital
Kohtla-Järve, Ida-Viru County, Estonia
|
| 11 |
NCT01290081 |
Completed |
Enhanced Tuberculosis Case Detection Among Substitution Treatment Patients |
|
- Other: Case management approach in referral to health care services
|
Interventional |
Not Applicable |
- National Institute for Health Development, Estonia
- LLC Corrigo
- Ida-Viru Central Hospital, Department of Tuberculosis
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
|
112 |
All |
18 Years and older (Adult, Senior) |
NCT01290081 |
TBIDU-1230 |
TBIDU |
October 2007 |
January 2008 |
January 2008 |
February 4, 2011 |
February 4, 2011 |
|
- LLC Corrigo
Jõhvi, Ida-Virumaa, Estonia
|
| 12 |
NCT01248338 |
Completed |
Effects of Nebivolol Versus Metoprolol Succinate on Endothelial Function |
|
- Drug: metoprolol succinate
- Drug: Nebivolol
|
Interventional |
Phase 4 |
- Berlin-Chemie AG Menarini Group
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Effects of nebivolol and metoprolol on endothelial function
- Change in carotid artery intima-media thickness
- Change in left ventricular mass index, systolic and diastolic function
- Arterial Compliance
|
80 |
All |
30 Years to 65 Years (Adult) |
NCT01248338 |
MeES/05/Neb-EnD/001 |
NEMENDAS |
March 2006 |
December 2008 |
December 2009 |
November 25, 2010 |
November 25, 2010 |
|
- Cardiology Clinic of Tartu University Clinics
Tartu, Estonia
|
| 13 |
NCT01062633 |
Unknown † |
Effect of Erythritol and Xylitol on Dental Caries Prevention in Children |
|
- Dietary Supplement: A, erythritol
- Dietary Supplement: xylitol
- Dietary Supplement: C, sorbitol
|
Interventional |
Phase 2
Phase 3 |
- University of Tartu
- University of Turku
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- caries reduction
- Depression of oral microorganisms
|
450 |
All |
7 Years to 9 Years (Child) |
NCT01062633 |
N012/95
VARST 07264 2008-2011 |
|
January 2008 |
February 2011 |
November 2011 |
February 4, 2010 |
February 4, 2010 |
|
- Department of Stomatology, University of Tartu
Tartu, Estonia
|
| 14 |
NCT00824226 |
Completed |
Magnesium Treatment in Hypoparathyroidism |
|
- Dietary Supplement: magnesium
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Calcium level at the end of magnesium treatment compared to pretreatment level
- Calcium level after stopping treatment compared to the level at the end of magnesium treatment
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT00824226 |
UT296 |
|
January 2009 |
August 2011 |
August 2011 |
January 16, 2009 |
August 29, 2011 |
|
- Tartu University Hospital
Tartu, Estonia
|
| 15 |
NCT00773760 |
Unknown † |
MOR and COMT SNP Polymorphism and Pain |
|
|
Observational |
|
- East Tallinn Central Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Postoperative assessments include PCA use (e.g., number of patient demands, total morphine administered) in each 24-h interval during the 48-h study period - primary endpoint.
- No secondary outcome endpoint
|
100 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00773760 |
ITK-1 |
|
October 2008 |
October 2009 |
December 2009 |
October 16, 2008 |
August 6, 2009 |
|
- Yuri Kolesnikov MD PhD
Tallinn, Estonia
|
| 16 |
NCT00763685 |
Terminated |
Study to Evaluate the Efficacy of Pre-operative Administration of Etoricoxib 120 mg, Etoricoxib 120 mg and Paracetamol 1 g Combination or Placebo in the Treatment of Postoperative Pain in Patients Undergoing Gynaecologic Laparoscopic Surgery |
|
|
Interventional |
Phase 4 |
- East Tallinn Central Hospital
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
|
40 |
Female |
18 Years to 50 Years (Adult) |
NCT00763685 |
35195
EUDRACT 2008-004098-17 |
|
June 2010 |
November 2011 |
November 2011 |
October 1, 2008 |
January 31, 2012 |
|
- East Tallinn Central Hospital
Tallinn, Estonia
|
| 17 |
NCT00721318 |
Unknown † |
A Prevalence Study of Chronic Widespread Pain (CWP) Among Patients With Rheumatoid Arthritis (RA) and Control Population in Tallinn and Harjumaa County |
|
|
Observational |
|
- Estonian Society for Rheumatology
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
|
6000 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00721318 |
Merck35016
35016 |
|
May 2008 |
May 2009 |
May 2010 |
July 24, 2008 |
July 24, 2008 |
|
- East Tallinn Central Hospital
Tallinn, Estonia
|
| 18 |
NCT00524758 |
Completed |
Oculusgen (Ologen) Glaucoma MMC Control in Estonia |
- Open Angle Glaucoma
- Angle Closure Glaucoma
- Uveitis Glaucoma
- (and 3 more...)
|
- Device: ologen (oculusgen) collagen matrix
- Drug: MMC in Trabeculectomy
|
Interventional |
Phase 3 |
- Pro Top & Mediking Company Limited
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- IOP <21mmHg without anti glaucoma medication
- IOP<21mmHg or IOP drops more than 30% with anti glaucoma medication
|
20 |
All |
19 Years and older (Adult, Senior) |
NCT00524758 |
oculusgen 2006-02-20 |
|
July 2007 |
October 2011 |
October 2011 |
September 5, 2007 |
June 27, 2017 |
|
- Tartu University Clinics
Tartu, Estonia
|
| 19 |
NCT00337818 |
Completed
Has Results |
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women |
- Papillomavirus Type 16/18 Infection
- Cervical Intraepithelial Neoplasia
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies
- Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervical Samples
- Titers of Anti-HPV-16 and Anti-HPV-18 Immunoglobulin G (IgG) Antibodies in Blood Samples
- (and 2 more...)
|
770 |
Female |
10 Years to 25 Years (Child, Adult) |
NCT00337818 |
107476 (M18)
107477
107479
107481 |
|
June 2006 |
June 2006 |
January 2009 |
June 16, 2006 |
May 30, 2017 |
March 2, 2010 |
- GSK Investigational Site
Tallinn, Estonia
|
| 20 |
NCT03431844 |
Recruiting |
Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation |
- Myocardial Ischemia
- Coronary Artery Bypass Surgery
|
|
Observational |
|
- University of Tartu
- Tartu University Hospital
- North Estonia Medical Centre
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Mortality
- Major complications: myocardial infarction.
- Major complications: acute kidney injury.
- Major complications: stroke.
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03431844 |
HN1160 |
|
January 1, 2018 |
December 31, 2018 |
June 1, 2019 |
February 13, 2018 |
February 13, 2018 |
|
- North Estonia Medical Centre
Tallinn, Harjumaa, Estonia - Tartu University Hospital
Tartu, Tartumaa, Estonia
|
| 21 |
NCT03231280 |
Completed |
A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee |
|
- Device: SB-061
- Other: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Symic OA Co.
- Nordic Bioscience A/S
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain
- Incidence of Treatment-Emergent Adverse Events
- Physical function
|
60 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT03231280 |
TP-1803 |
MODIFY2 |
August 14, 2017 |
December 18, 2017 |
March 27, 2018 |
July 27, 2017 |
April 19, 2018 |
|
- CCBR
Tallinn, Estonia - Medita Kliinik
Tartu, Estonia
|
| 22 |
NCT02802709 |
Completed |
A Trial of SB-061 in Osteoarthritis of the Knee |
|
- Device: SB-061
- Other: Placebo
|
Interventional |
Phase 1
Phase 2 |
- Symic OA Co.
- Nordic Bioscience Clinical Development
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Pain
- Incidence of Treatment-Emergent Adverse Events
- Physical function
|
90 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02802709 |
TP-1621 |
MODIFY-OA |
May 2016 |
February 2017 |
June 2017 |
June 16, 2016 |
January 4, 2018 |
|
- CCBR
Tallinn, Estonia - Medita Kliinik
Tartu, Estonia
|
| 23 |
NCT01840332 |
Completed |
Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer |
|
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- TSH level at the end of study
- change in Billewitz index during the study
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT01840332 |
1.0 /29.08.2012 |
|
April 2013 |
February 2014 |
February 2014 |
April 25, 2013 |
March 14, 2014 |
|
- East Tallinn Central Hospital
Tallinn, Estonia - Tartu University Hospital
Tartu, Estonia
|
| 24 |
NCT01789138 |
Completed
Has Results |
Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia |
- HIV
- AIDS
- Medication Adherence
|
- Behavioral: Situated Optimal Adherence Intervention
|
Interventional |
Not Applicable |
- University of Tartu
- National Institute for Health Development, Estonia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure)
- HIV-1 RNA Count / Viral Load (VL)
|
519 |
All |
18 Years and older (Adult, Senior) |
NCT01789138 |
SARTH12115T
3.2.1001.11-0020 |
|
January 2013 |
November 2014 |
December 2014 |
February 11, 2013 |
March 10, 2016 |
February 2, 2016 |
- West-Tallinn Central Hospital
Tallinn, Harju County, Estonia - East-Viru Central Hospital
Kohtla-Järve, Ida-Viru County, Estonia
|
| 25 |
NCT00487019 |
Completed |
Management of Early Onset Neonatal Septicaemia: Selection of Optimal Antibacterial Regimen for Empiric Treatment |
- Early Onset Neonatal Sepsis
|
|
Observational |
|
- University of Tartu
- Estonian Science Foundation
- ESPID Small grant award
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
281 |
All |
up to 72 Hours (Child) |
NCT00487019 |
038FAR042005 |
|
August 2006 |
|
December 2007 |
June 15, 2007 |
May 29, 2008 |
|
- Tallinń's Childrens Hospital, Paediatric Intensive Care Unit
Tallinn, Estonia - Tartu University Clinics, Department of Paediatric Intensive Care
Tartu, Estonia
|
| 26 |
NCT03502525 |
Recruiting
New |
Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use |
- Substance Abuse, Intravenous
- Prevention and Control
|
- Behavioral: Break the Cycle Intervention
|
Interventional |
Not Applicable |
- Icahn School of Medicine at Mount Sinai
- University of Tartu
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of participants helping with first injections
- Number of participants who say positive things
- Number of participants injecting in front of other people
- Number of participants offering to give first injection
|
400 |
All |
18 Years and older (Adult, Senior) |
NCT03502525 |
GCO 15-1445
5DP1DA039542-05 |
|
August 31, 2016 |
March 2020 |
March 2020 |
April 18, 2018 |
April 23, 2018 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States - University of Tartu
Tallinn, Estonia
|
| 27 |
NCT00982930 |
Completed |
Open Label Extension to Bridging Study CTBM100C2303 |
- Pseudomonas Aeruginosa
- Cystic Fibrosis
|
- Drug: Tobramycin inhalation powder
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of tobramycin inhalation powder for the treatment of infections with P. aeruginosa in subjects suffering from cystic fibrosis.
- Efficacy of tobramycin inhalation powder, assessed by spirometry
- Density of microorganisms in sputum samples
|
57 |
All |
6 Years to 21 Years (Child, Adult) |
NCT00982930 |
CTBM100C2303E1
EudraCT 2008-004764-39 |
|
August 2009 |
October 2011 |
|
September 23, 2009 |
November 16, 2016 |
|
- Novartis Investigative Site
Tallin, Estonia - Novartis Investigative Site
Yaroslavl, Russian Federation
|
| 28 |
NCT01663506 |
Completed
Has Results |
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab) |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With Tocilizumab Treatment at 6 Months After Treatment Initiation
- Percentage of Participants With Tocilizumab Treatment at 12 Months After Treatment Initiation
- Percentage of Participants With Tocilizumab Dose Modification, Interruption, and Irregularity
- (and 23 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01663506 |
ML28311 |
|
April 2012 |
September 2014 |
September 2014 |
August 13, 2012 |
December 9, 2015 |
December 9, 2015 |
- Tallinn, Estonia
- Tallinn, Estonia
- Tartu, Estonia
|
| 29 |
NCT00633074 |
Completed
Has Results |
Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations |
|
- Biological: Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)
- Biological: Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Serum Haemagglutination-inhibition (HI) Antibody Titer Against the Three Vaccine Strains
- Number of Subjects Seropositive for HI Antibodies Against the Three Vaccine Strains
- Number of Subjects Seroconverted for HI Antibodies Against the Three Vaccine Strains
- (and 9 more...)
|
720 |
All |
65 Years and older (Adult, Senior) |
NCT00633074 |
111454 |
|
March 2008 |
April 2008 |
April 2008 |
March 11, 2008 |
December 16, 2016 |
May 28, 2012 |
- GSK Investigational Site
Saku, Estonia - GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tartu, Estonia
|
| 30 |
NCT01755689 |
Completed |
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults |
- Infections, Meningococcal
|
- Biological: Meningococcal vaccine GSK134612
- Biological: Cervarix®
- Biological: Boostrix®
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Immunogenicity with respect to components of the investigational vaccine in terms of antibody titres.
- Immunogenicity with respect to the components of Cervarix in terms of antibody titres.
- Immunogenicity with respect to the components of Boostrix in terms of antibody concentrations.
- (and 7 more...)
|
1300 |
Female |
9 Years to 25 Years (Child, Adult) |
NCT01755689 |
113823
2012-001876-13 |
|
January 2013 |
April 2014 |
April 2014 |
December 24, 2012 |
January 18, 2017 |
|
- GSK Investigational Site
Santo Domingo, Dominican Republic - GSK Investigational Site
Tartu, Estonia - GSK Investigational Site
Bangkok, Thailand
|
| 31 |
NCT01424137 |
Completed |
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF) |
- Asthma
- Chronic Obstructive Pulmonary Disease
|
- Device: Easyhaler type A
- Device: Easyhaler type B
- Device: Diskus inhaler
|
Interventional |
Not Applicable |
- Orion Corporation, Orion Pharma
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
|
- Peak inspiratory flow rate through the placebo Easyhaler and Diskus inhalers
- The inspiratory volume through the placebo Easyhaler and Diskus inhalers will be measured at the same time with the peak inspiratory flow rate
|
227 |
All |
4 Years and older (Child, Adult, Senior) |
NCT01424137 |
3106002 |
SALIF |
September 2011 |
November 2011 |
November 2011 |
August 26, 2011 |
February 3, 2012 |
|
- Lasnamäe Medicum
Tallinn, Estonia - Children's Clinic of Tartu, Allergy Centre
Tartu, Estonia - Tartu University Hospital, Lung Clinic
Tartu, Estonia - (and 2 more...)
|
| 32 |
NCT00196716 |
Completed
Has Results |
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease |
|
- Biological: Fabrazyme (agalsidase beta)
|
Interventional |
Phase 2 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Globotriaosylceramide (GL-3) Clearance in Kidney Interstitial Capillary Endothelium
- Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium
- Estimated Glomerular Filtration Rate (eGFR)
- (and 2 more...)
|
21 |
Male |
16 Years and older (Child, Adult, Senior) |
NCT00196716 |
AGAL-017-01 |
|
June 2003 |
April 2006 |
March 2007 |
September 20, 2005 |
April 3, 2015 |
April 2, 2009 |
- II. interní klinika 1. LF UK
Praha 2, Czech Republic - Tartu University Clinics, Department of Internal Medicine
Tartu, Estonia - Klinika Chorob Metabolicznych, Instytut "Pomnik-Centrum Zdrowia Dziecka"
Warsaw, Poland - Detská fakultná nemocnica Kramáre I. Interná klinika
Bratislava 37, Slovakia
|
| 33 |
NCT01751165 |
Completed
Has Results |
Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older |
|
- Biological: Herpes zoster vaccine GSK1437173A
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of Subjects With Vaccine Response to Anti-glycoprotein E (Anti-gE) Antibodies as Determined by the Enzyme-linked Immunosorbent Assay (ELISA).
- Concentrations of Antibodies Against Anti-gE as Determined by ELISA.
- Number of Subjects With Solicited Local Symptoms.
- (and 8 more...)
|
354 |
All |
50 Years and older (Adult, Senior) |
NCT01751165 |
116697
2012-004456-11 |
|
March 2013 |
May 2014 |
April 2015 |
December 17, 2012 |
March 31, 2017 |
March 31, 2017 |
- GSK Investigational Site
Spring Valley, California, United States - GSK Investigational Site
Wichita, Kansas, United States - GSK Investigational Site
Uniontown, Pennsylvania, United States - GSK Investigational Site
Tartu, Estonia
|
| 34 |
NCT01321723 |
Completed
Has Results |
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women |
- Postmenopausal Osteoporosis
|
- Drug: PTH analog
- Drug: Placebo
- Drug: Forsteo (Teriparatide)
|
Interventional |
Phase 2 |
- Unigene Laboratories Inc.
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- % Change From Baseline BMD in L1-L4 Axial Lumbar Spine at Week 24
- % Change From Baseline in Bone Resorption Marker (CTx-1) at Week 24
- Systemic Absorption of PTH at Week 24
- % Change From Baseline in Bone Formation Marker (P1NP) at Week 24
|
97 |
Female |
45 Years to 80 Years (Adult, Senior) |
NCT01321723 |
UGL-OR1001 |
|
February 2011 |
October 2011 |
October 2011 |
March 23, 2011 |
March 1, 2013 |
February 21, 2013 |
- CCBR
Aalborg, Denmark - CCBR
Ballerup, Denmark - CCBR
Vejle, Denmark - CCBR
Tallinn, Estonia
|
| 35 |
NCT02951403 |
Recruiting |
Results of the Treatment of Patients With Elbow Osteoarthritis |
|
- Procedure: Elbow arthroscopy
- Other: Conservative treatment
|
Interventional |
Not Applicable |
- Tampere University Hospital
- Helsinki University Central Hospital
- Central Finland Hospital District
- (and 2 more...)
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Quick DASH score
- VAS score
- Range of motion
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02951403 |
R15117 |
|
January 2016 |
December 2020 |
December 2020 |
November 1, 2016 |
March 23, 2018 |
|
- Regional Hospital of North Estonia
Tallinn, Estonia - Töölö Hospital
Helsinki, Finland - Central Finland Central Hospital
Jyväskylä, Finland - (and 2 more...)
|
| 36 |
NCT03409679 |
Recruiting |
Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa |
|
- Drug: Murepavadin
- Drug: Two anti-pseudomonal antibiotics
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03409679 |
POL7080-011 |
PRISM-MDR |
March 23, 2018 |
May 2020 |
July 2020 |
January 24, 2018 |
April 2, 2018 |
|
- Tartu University Hospital
Tartu, Estonia - South Estonian Hospital Ltd
Võru, Estonia - CHU Limoges
Limoges, France - (and 3 more...)
|
| 37 |
NCT02455999 |
Completed |
Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain |
- Ocular Pain
- Dry Eye Syndrome
|
- Drug: SYL1001
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from the baseline scoring of eye pain on the Visual Analogue Scale (VAS)
- Change from the baseline scoring of ocular discomfort in the Ocular Surface Disease Index (OSDI)
- Change from the baseline scoring after fluorescein staining of the cornea
- (and 5 more...)
|
66 |
All |
18 Years and older (Adult, Senior) |
NCT02455999 |
SYL1001_III |
|
June 2015 |
March 2016 |
|
May 28, 2015 |
April 5, 2016 |
|
- East Tallinn Central Hospital
Tallinn, Estonia - Eye Clinic Dr. Krista Turman
Tallinn, Estonia - Hospital Universitario Ramón y Cajal
Madrid, Spain - (and 3 more...)
|
| 38 |
NCT01482364 |
Completed |
BEtter Control of Blood Pressure in Hypertensive pAtients Monitored Using the HOTMAN® sYstem |
|
- Device: Integrated hemodynamic management (IHM) - HOTMAN System
- Device: Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Absolute change in daytime SBP, under ambulatory conditions (ABPM) after a 6 months follow-up.
- The percentage of normalization of SBP (<135 mmHg) at ABPM
- The absolute change from baseline in 24h SBP-ABPM, in 24h DBP-ABPM
- (and 2 more...)
|
183 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01482364 |
HS-01-2011 |
BEAUTY |
October 2011 |
June 2013 |
January 2014 |
November 30, 2011 |
March 24, 2015 |
|
- Tallinn Hypertension Excellence Centre
Tallin, Estonia - Hôpital européen Georges Pompidou
Paris, France - Milano Hypertension Excellence Center
Milano, Italy - (and 2 more...)
|
| 39 |
NCT01753453 |
Completed |
An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells |
|
- Drug: Plerixafor
- Drug: Granulocyte-colony stimulating factor (G-CSF)
|
Interventional |
Phase 2 |
- Sanofi
- Genzyme, a Sanofi Company
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/CD34+ cells
- The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/plerixafor cumulative dose/kg body weights
- The presence of myeloma tumor cells as measured by the percentage of myeloma tumor cells/G-CSF cumulative dose/kg body weight
- (and 6 more...)
|
23 |
All |
18 Years and older (Adult, Senior) |
NCT01753453 |
ARD12858
MOZ23510
2011-004783-30 |
|
June 2013 |
September 2016 |
September 2016 |
December 20, 2012 |
October 7, 2016 |
|
- Investigational Site Number 056002
Brugge, Belgium - Investigational Site Number 233001
Tallinn, Estonia - Investigational Site Number 440001
Vilnius, Lithuania - (and 2 more...)
|
| 40 |
NCT01424501 |
Terminated
Has Results |
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease |
|
- Biological: GSK Biologicals' investigational TB vaccine GSK 692342
- Biological: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of Subjects With Solicited Local Symptoms
- Number of Subjects With Solicited General Symptoms
- Number of Subjects With Adverse Events (AEs)
- (and 9 more...)
|
142 |
All |
18 Years to 59 Years (Adult) |
NCT01424501 |
114886 |
|
November 2011 |
April 2014 |
April 2014 |
August 29, 2011 |
January 24, 2017 |
January 24, 2017 |
- GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tartu, Estonia - GSK Investigational Site
Taipei, Taiwan - (and 3 more...)
|
| 41 |
NCT00938392 |
Completed
Has Results |
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly |
|
- Biological: GSK investigational FluNG vaccine GSK2186877A, aged lot
- Biological: GSK investigational FluNG vaccine GSK2186877A, fresh lot
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Serum Haemagglutination-Inhibition (HI) Antibody Titers Against the 3 Vaccine Strains
- Number of Subjects Seropositive Against the 3 Vaccine Strains
- Number of Subjects Seroconverted for the 3 Vaccine Strains
- (and 7 more...)
|
726 |
All |
65 Years and older (Adult, Senior) |
NCT00938392 |
112662 |
|
July 2009 |
October 2009 |
October 2009 |
July 13, 2009 |
November 16, 2016 |
May 17, 2012 |
- GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tartu, Estonia - GSK Investigational Site
Bratislava, Slovakia - (and 3 more...)
|
| 42 |
NCT02913521 |
Completed |
Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1% |
|
- Drug: Diclofenac Sodium Gel 1%
- Drug: Voltaren Gel
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change from Baseline to Week 8 in WOMAC Pain Scale
- Superiority of Test and Reference against Placebo in the Mean Change from Baseline to Week 8 in the total WOMAC Pain score.
- Incidences of treatment emergent adverse events
- (and 2 more...)
|
796 |
All |
35 Years and older (Adult, Senior) |
NCT02913521 |
P130021 |
|
June 2015 |
April 2016 |
June 2016 |
September 23, 2016 |
September 23, 2016 |
|
- Tabasalu Perearstikeskus OU
Harjumaa, Estonia - Vee Family Doctor's Center OY
Paide, Estonia - OU Mai Perearstid
Parnu, Estonia - (and 52 more...)
|
| 43 |
NCT02892344 |
Recruiting |
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma |
|
- Drug: QMF149 150/80 μg
- Drug: MF 200 μg
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- trough FEV1
- ACQ-7
- trough FEV1 at day 2
- (and 11 more...)
|
1000 |
All |
12 Years to 75 Years (Child, Adult, Senior) |
NCT02892344 |
CQVM149B2303
2016-000472-22 |
|
May 17, 2010 |
August 31, 2018 |
August 31, 2018 |
September 8, 2016 |
June 15, 2017 |
|
- Novartis Investigative Site
Kohtla-Jarve, Estonia - Novartis Investigative Site
Tallinn, Estonia - Novartis Investigative Site
Tallinn, Estonia - (and 44 more...)
|
| 44 |
NCT01716520 |
Completed
Has Results |
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg |
- Pulmonary Disease, Chronic Obstructive
|
- Device: Umeclidinium/Vilanterol 62.5/25 mcg
- Device: Umeclidinium 62.5 mcg
- Device: Vilanterol 25 mcg
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type
- Number of Participants (Par.) Who Were Responsive to UMEC/VI, UMEC, or VI According to FEV1 at Day 1 of Each Treatment Period (TP)
- Number of Participants With a Larger Change From Baseline in 0-6 Hour Weighted Mean FEV1 at Day 14 of Each Treatment Period With UMEC/VI Compared With UMEC and VI Alone
- Change From Baseline in Trough FEV1 on Day 15 of Each Treatment Period
|
182 |
All |
40 Years and older (Adult, Senior) |
NCT01716520 |
116133 |
|
October 2012 |
March 2013 |
March 2013 |
October 30, 2012 |
January 9, 2017 |
February 11, 2014 |
- GSK Investigational Site
Haapsalu, Estonia - GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tallinn, Estonia - (and 18 more...)
|
| 45 |
NCT01100073 |
Completed
Has Results |
Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of Life |
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at the End of Maintenance
- Change From Baseline in UPDRS Part III Score at the End of Maintenance
- Change From Baseline in Spiralometry Measurement at the End of Maintenance (Right Hand)
- (and 9 more...)
|
1703 |
All |
Child, Adult, Senior |
NCT01100073 |
248.657 |
|
February 2008 |
August 2009 |
|
April 8, 2010 |
April 11, 2014 |
September 20, 2010 |
- Boehringer Ingelheim Investigational Site 5
Keila, Estonia - Boehringer Ingelheim Investigational Site 4
Kohtla-Järve, Estonia - Boehringer Ingelheim Investigational Site 6
Rakvere, Estonia - (and 212 more...)
|
| 46 |
NCT01144663 |
Completed |
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines |
- Infections, Meningococcal
|
- Biological: Meningococcal vaccine GSK134612
- Biological: MenC-CRM197
- Biological: MenC-TT
- (and 2 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Immunogenicity with respect to components of the investigational vaccine.
- Immunogenicity with respect to components of the investigational vaccine (on secondary readouts).
- Immunogenicity with respect to components of the co-administered pneumococcal conjugate vaccine.
- (and 5 more...)
|
2095 |
All |
6 Weeks to 12 Weeks (Child) |
NCT01144663 |
113369 |
|
July 2010 |
June 2012 |
September 2013 |
June 15, 2010 |
May 19, 2014 |
|
- GSK Investigational Site
Haabneeme, Estonia - GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tallinn, Estonia - (and 46 more...)
|
| 47 |
NCT01319019 |
Completed |
A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: GSK961081
- Drug: Salmeterol
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in FEV1 from baseline in pre-dose AM trough.
- Weighted Mean and Serial FEV1 at multiple timepoints
|
437 |
All |
40 Years and older (Adult, Senior) |
NCT01319019 |
115032 |
|
December 2010 |
September 2011 |
September 2011 |
March 21, 2011 |
December 1, 2016 |
|
- GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tallinn, Estonia - GSK Investigational Site
Tallinn, Estonia - (and 46 more...)
|
| 48 |
NCT03165617 |
Active, not recruiting |
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age |
|
- Biological: QIVc
- Biological: Non-influenza Comparator Vaccine
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Efficacy: Absolute vaccine efficacy of QIVc by first occurrence Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) or culture confirmed influenza, due to any influenza Type A and B strain in subjects ≥2 years to <18 years of age
- Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain in subjects ≥3 years to <18 years of age
- Efficacy: Absolute vaccine efficacy of QIVc by first occurrence RT-PCR or culture confirmed influenza, due to any influenza Type A and B strain by age subgroup
- (and 12 more...)
|
7692 |
All |
2 Years to 17 Years (Child) |
NCT03165617 |
V130_12
2016-002883-15 |
|
May 24, 2017 |
June 30, 2019 |
July 30, 2019 |
May 24, 2017 |
March 15, 2018 |
|
- AusTrials Pty Ltd
Sherwood, Queensland, Australia - Murdoch Childrens Research Institute
Carlton, Victoria, Australia - Merekivi Family Doctors Ltd
Tallinn, Harjumaa, Estonia - (and 9 more...)
|
| 49 |
NCT03381196 |
Recruiting |
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications |
|
- Drug: Pimodivir 600 mg
- Drug: Placebo
- Other: SOC Treatment
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Time to Resolution of Influenza-Related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ)
- Number of Participants With Adverse Events as a Measure of Safety and Tolerability
- Number of Participants With Laboratory Abnormalities as a Measure of Safety and Tolerability
- (and 17 more...)
|
720 |
All |
13 Years to 85 Years (Child, Adult, Senior) |
NCT03381196 |
CR108400
2017-002217-59
63623872FLZ3002 |
|
January 18, 2018 |
May 19, 2019 |
October 29, 2019 |
December 21, 2017 |
April 25, 2018 |
|
- Cahaba Research Inc
Birmingham, Alabama, United States - Scottsboro Quick Care Clinic
Scottsboro, Alabama, United States - Research Center of Fresno Inc
Fresno, California, United States - (and 414 more...)
|
| 50 |
NCT02957682 |
Recruiting |
Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo |
|
- Drug: Praluent (Alirocumab)
- Drug: Placebo
|
Interventional |
Phase 4 |
- Regeneron Pharmaceuticals
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change in Cambridge Neuropsychological Test Automated Battery cognitive domain Spatial Working Memory strategy score
- Exploratory neurocognitive Paired Associates Learning (PAL); defined as both a PAL z-score change from baseline and PAL raw score change from baseline
- Exploratory neurocognitive Reaction Time (RTI); RTI z-score change from baseline and RTI raw score change from baseline
- (and 12 more...)
|
2170 |
All |
40 Years to 85 Years (Adult, Senior) |
NCT02957682 |
R727-CL-1532
2016-003189-16 |
|
November 18, 2016 |
August 2020 |
August 2020 |
November 8, 2016 |
January 5, 2018 |
|
- Alexander City, Alabama, United States
- Birmingham, Alabama, United States
- Site 1
Mobile, Alabama, United States - (and 175 more...)
|
Create an RSS feed from your search for:
Download the search results for: